Human heart failure: cAMP stimulation of SR Ca2+-ATPase activity and phosphorylation level of phospholamban

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 277, Issue 2 46-2, 1999, Pages

  Schmidt, Ulrich ^a   Hajjar, Roger J ^b   Kim, Catherine S ^a   Lebeche, Djamel ^a   Doye, Angelia A ^c   Gwathmey, Judith K ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Inst Cardiovasc Dis Muscle Res   (United States)

Author keywords

Adenosine 3',5' cyclic monophosphate; Calcium ion; Calcium ion adenosinetriphosphatase; Human myocardium; Phospholamban; Sarcoplasmic reticulum

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; PHOSPHOLAMBAN;

ADULT; ARTICLE; CALCIUM MOBILIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HEART FAILURE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SARCOPLASMIC RETICULUM;

EID: 0032865827     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.1999.277.2.h474     Document Type: Article

References (34)

1. Bartel, S., B. Stein, T. Eschenhagen, U. Mende, J. Neumann, W. Schmitz, E. G. Krause, P. Karczewski, and H. Scholz. Protein phosphorylation inisolated trabeculae from non-failing and failing human hearts. Mol. Cell. Biochem. 157: 171-179, 1996.
2. Böhm, M., B. Reiger, R. H. G. Schwinger, and E. Erdmann. cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in non-failing and failing myocardium. Cardiovasc. Res. 28: 1713-1719, 1994.
3. Chu, A., M. C. Dixon, A. Saito, S. Seiler, and S. Fleischer. Isolation of sarcoplasmic reticulum fractions referable to longitudinal tubules and junctional terminal cisternae from rabbit skeletal muscle. Methods Enzymol. 157: 36-46, 1988.
4. Fabiato, A. Computer programs for calculating total from specified free or free from specified total ionic concentrations in aqueous solutions containing multiple metals and ligands. Methods Enzymol. 157: 378-417, 1988.
5. Feldman, A., E. O. Weinberg, P. Ray, and B. H. Lorell. Selective changes in gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circ. Res. 73: 184-192, 1993.
6. Feldman, M. D., L. Copelas, J. K. Gwathmey, P. Phillips, S. E. Warren, F. J. Schoen, W. Grossman, and J. P. Morgan. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 75: 331-339, 1987.
7. 2+ ATPase and phospholamban mRNA and protein levels in end-stage heart failure due to ischemic or dilated cardiomyopathy. J. Mol. Med. 74: 321-332, 1996.
8. Gwathmey, J. K., L. Copelas, R. MacKinnon, F. J. Schoen, M. D. Feldman, W. Grossman, and J. P. Morgan. Abnormal intracellular calcium handling in myocardium from patients with endstage heart failure. Circ. Res. 61: 70-76, 1987.
9. Gwathmey, J. K., M. T. Slawsky, R. J. Hajjar, G. M. Briggs, and J. P. Morgan. Role of intracellular calcium handling in force-interval relationship of human ventricular myocardium. J. Clin. Invest. 85: 1599-1613, 1990.
10. 2+-ATPase. Circ. Res. 81: 145-153, 1997.
11. 2+-ATPase in failing and nonfailing myocardium. Circ. Res. 75: 434-442, 1994.
12. Hoit, B. D., S. F. Khoury, E. G. Kranias, N. G. Ball, and R. A. Walsh. In vivo echocardiographic detection of enhanced left ventricular function in gene-targeted mice with phospholamban deficiency. Circ. Res. 77: 632-637, 1995.
13. Kadambi, V., S. Ponniah, J. M. Harrer, B. D. Hoit, G. W. Dorn, R. A. Walsh, and E. G. Kranias. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J. Clin. Invest. 97: 533-539, 1996.
14. Koss, K. L., and E. G. Kranias. Phospholamban: a prominent regulator of myocardial contractility. Circ. Res 79: 1059-1063, 1996.
15. 2+-ATPase in failing and nonfailing human hearts. Cardiovasc. Res. 31: 625-632, 1996.
16. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
17. Luo, W., I. L. Grupp, J. Harrer, S. Ponniah, G. Grupp, J. J. Duffy, T. Doetschman, and E. Kranias. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation. Circ. Res. 75: 401-409, 1994.
18. Luo, W., B. M. Wolska, I. L. Grupp, J. M. Harrer, K. Haghighi, D. G. Ferguson, J. P. Slack, G. Grupp, T. Doetschman, R. J. Solaro, and E. G. Kranias. Phospholamban gene dosage effects in the mammalian heart. Circ. Res. 78: 839-847, 1996.
19. 2+-ATPase gene expression in the human ventricle during end-stage heart failure. J. Clin. Invest. 85: 305-309, 1990.
20. Mercadier, J. J., A. M. Lompre, B. Swynghedauw, and K. Schwartz. Plasticity of myocardial phenotype during cardiac hypertrophy and failure. Bull. Acad. Natl. Med. 177: 917-931, 1993.
21. Movsesian, M. A. Calcium uptake and release by cardiac sarcoplasmic reticulum. In: Heart Failure Basic Science and Clinical Aspects, edited by J. K. Gwathmey, G. M. Briggs, and P. D. Allen. New York: Dekker, 1993, p. 101-120.
22. 2+ uptake in sarcoplasmic reticulum from normal and failing hearts. J. Clin. Invest. 85: 1698-1702, 1990.
23. 2+-transporting ATPase, phospholamban, and calsequestrin levels in non-failing and failing human myocardium. Circulation 90: 653-657, 1994.
24. Mulieri, L. A., B. J. Leavitt, B. J. Martin, J. R. Haeberle, and N. R. Alpert. Myocardial force-frequency defect in mitral regurgitation heart failure is reversed by forskolin. Circulation 88: 2700-2704, 1993.
25. 2+-and ATP-cycling imbalances in end-stage dilated and ischemic cardiomyopathies. Cardiovasc. Res. 30: 394-404, 1995.
26. Phillips, P. J., J. K. Gwathmey, M. D. Feldman, F. J. Schoen, W. Grossman, and J. P. Morgan. Post-extrasystolic potentiation and the force-frequency relationship: differential augmentation of myocardial contractility in working myocardium from patients with end-stage heart failure. J. Mol. Cell. Cardiol. 22: 99-110, 1990.
27. Rockman, H. A., S. Ono, R. S. Ross, L. R. Jones, M. Karimi, V. Bhargava, J. Ross, and K. R. Chien. Molecular and physiological alterations in murine ventricular dysfunction. Proc. Natl. Acad. Sci. USA 91: 2694-2698, 1994.
28. Schmidt, U., R. J. Hajjar, P. A. Helm, C. S. Kim, A. A. Doye, and J. K. Gwathmey. Contribution of abnormal sarcoplasmic reticulum ATPase activity to systolic and diastolic dysfunction in human heart failure. J. Mol. Cell. Cardiol. 30: 1929-1937, 1998.
29. Schwinger, R. H. G., M. Böhm, J. Müller-Ehmsen, R. Uhlmann, U. Schmidt, A. Stäblein, P. Überfuhr, E. Kreuzer, B. Reichart, H. J. Eissner, and E. Erdmann. Effect of inotropic stimulation on the negative force frequency relationship in the failing human heart. Circulation 88: 2267-2276, 1993.
30. 2+ ATPase activity of cardiac sarcoplasmic reticulum from patients with dilated cardiomyopathy compared to non-failing patients. Circulation 92: 3220-3228, 1995.
31. Tada, M., and A. M. Katz. Phosphorylation of the sarcoplasmic reticulum and sarcolemma. Annu. Rev. Physiol. 44: 401-423, 1982.
32. 2+-ATPase gene. Circ. Res. 71: 9-17, 1992.
33. 2+-ATPase of cardiac sarcoplasmic reticulum are critical for functional association with phospholamban. J. Biol. Chem. 269: 22929-22932, 1994.
34. Voss, J., L. R. Jones, and D. D. Thomas. The physical mechanisms of calcium pump regulation in the heart. Biophys. J. 67: 190-196, 1994.